JGJohn G. Gums

John G. Gums

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John G. Gums has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Building on the 2025 national academies pharmacy workshop: ensuring access to community pharmacist care

    by Jennifer L Bacci, Stuart Beatty, John G Gums, Patricia H Fabel, Kyle Melin

    Growing medication use, chronic disease burden, and primary care provider shortages have intensified the need for additional models of care delivery in the United States. Community pharmacists are uniquely positioned to help address these challenges through medication management, chronic disease management, and timely access to care. Evidence demonstrates that pharmacist services improve medication use and therapeutic outcomes while lowering overall health care costs. Despite these benefits, pharmacists remain underutilized as patient care providers, largely due to inconsistent reimbursement and business models that continue to prioritize product dispensing over patient care. Building on the 2025 National Academies of Sciences, Engineering, and Medicine workshop, Innovations in Pharmacy Training and Practice to Advance Patient Care, this paper examines existing and proposed state and federal payment policies and how their design influences implementation and scalability in community pharmacy practice. Recommendations include broad medical benefit reimbursement across payers, broad patient and service eligibility, and deference to state-defined scope of practice. Additional reforms are needed to address implementation barriers related to electronic health record access and credentialing. Together, these reforms can support sustainable, scalable community pharmacist-provided care and improve care access, quality, and affordability.

  • Music‐Based Interventions in Clinical Pharmacy Practice: A Narrative Review of Mechanisms, Evidence, and a Framework for Integration

    by Hannah Webb, John G. Gums

    Music‐based interventions (MBIs) have emerged as a promising, nonpharmacologic approach to improving patient care across a variety of clinical settings. This narrative review examines the current evidence describing the mechanistic basis through which music engages biological pathways relevant to clinical pharmacy practice, and the clinical evidence supporting MBIs as adjuncts to pharmacotherapy across clinical outcomes. From this evidence, the review proposes a framework through which MBIs may be integrated into clinical practice that comprises: (1) patient selection, (2) MBI selection, and (3) outcome monitoring. The review does not constitute formal practice guidance, as pharmacy‐specific clinical protocols and implementation models remain active areas of research. Additionally, the review synthesizes emerging evidence supporting MBIs as a clinical pharmacy workforce well‐being strategy. Collectively, these findings highlight the potential for MBIs to serve as an innovative adjunct to traditional pharmacotherapy that aligns with the clinical pharmacist's existing responsibilities for medication optimization, deprescribing, and holistic, patient‐centered care.

  • National Assessment of Reimbursement Models for Clinical Faculty Services in Academic Pharmacy Practice

    by John G. Gums, Craig P. Henchey, Thomas C. Dowling, Donald A. Godwin, Paul O. Gubbins, Thomas G. Wadsworth, Kristin K. Wiisanen, Mark A. Munger

    Background: Colleges and Schools of Pharmacy (C/SoP) collect revenue from tuition and indirect cost recovery related to teaching and research. Clinical faculty services are frequently exchanged for experiential opportunities, but this practice undervalues pharmacists and their impact on patient care. Some C/SoP have adopted innovative strategies to secure reimbursement for faculty‐delivered patient care services, but they have not been well described. The objective is to describe academic pharmacist payment for clinical services and to provide recommendations on how to increase clinical service revenue based on a national survey of C/SoP. Methods: The 19‐item survey was distributed to 143 (71 public/72 private) C/SoP. The survey covered: faculty billing, insurance sources, state regulation, revenue models, and barriers. Results: The response rate was 73% (80% public, 65% private). Nearly all C/SoP provided clinical services (97%), but only 54% bill for those services. Many public (58%) and private (49%) C/SoP bill for clinical services. Offset revenue (39%) and flat‐fee contracts (19%) were the most common revenue models. The most common billable services included: Chronic Care Management (CCM) (79%), Medication Therapy Management (MTM) (71%), Immunizations (66%), and Annual Wellness Visits (45%). Of those utilizing incident‐to billing services, 78% bill at level 1, but only 33% bill at level 3 or higher. Nine C/SoP reported having an employee certified in medical billing. The main barriers to collecting revenue were sites being used only for faculty provision of academic service, legal regulations, lack of pharmacist provider status, cost and difficulty of billing, and lack of interest or knowledge. Conclusions: Current pharmacist care payment models indicate opportunities for all C/SoP to increase the revenue they collect from clinical services. All C/SoP should have a designated employee credentialed in medical billing and coding. Increased utilization of “incident‐to” billing can generate revenue for C/SoP regardless of what happens to pharmacist provider status federally.


  • Open Access

    Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers

    by Mai Mehanna, Caitrin W. McDonough, Steven M. Smith, Yan Gong, John G. Gums, Arlene B. Chapman, Julie A. Johnson, Rhonda M. Cooper‐DeHoff

    Hypertensive patients with a higher proportion of genetic West African ancestry (%GWAA) have better blood pressure (BP) response to thiazide diuretics (TDs) and worse response to β‐blockers (BBs) than those with lower %GWAA, associated with their lower plasma renin activity (PRA). TDs and BBs are suggested to reduce BP in the long term through vasodilation via incompletely understood mechanisms. This study aimed at identifying pathways underlying ancestral differences in PRA, which might reflect pathways underlying BP‐lowering mechanisms of TDs and BBs. Among hypertensive participants enrolled in the Pharmacogenomics Evaluation of Antihypertensive Responses (PEAR) and PEAR‐2 trials, we previously identified 8 metabolites associated with baseline PRA and 4 metabolic clusters (including 39 metabolites) that are different between those with GWAA <45% versus ≥45%. In the current study, using Ingenuity Pathway Analysis (IPA), we integrated these signals. Three overlapping metabolic signals within three significantly enriched pathways were identified as associated with both PRA and %GWAA: ceramide signaling, sphingosine 1‐ phosphate signaling, and endothelial nitric oxide synthase signaling. Literature indicates that the identified pathways are involved in the regulation of the Rho kinase cascade, production of the vasoactive agents nitric oxide, prostacyclin, thromboxane A2, and endothelin 1; the pathways proposed to underlie TD‐ and BB‐induced vasodilatation. These findings may improve our understanding of the BP‐lowering mechanisms of TDs and BBs. This might provide a possible step forward in personalizing antihypertensive therapy by identifying patients expected to have robust BP‐lowering effects from these drugs.


  • Open Access

    Circulating microRNA Biomarkers of Thiazide Response in Hypertension

    by Lakshmi Manasa S. Chekka, Marwa Tantawy, Taimour Langaee, Danxin Wang, Rolf Renne, Arlene B. Chapman, John G. Gums, Eric Boerwinkle, Rhonda M. Cooper‐DeHoff, Julie A. Johnson

    Background: Thiazide diuretics are the second most frequently prescribed class of antihypertensives, but up to 50% of patients with hypertension have minimal antihypertensive response to thiazides. We explored circulating microRNAs (miRNAs) in search of predictive biomarkers of thiazide response. Methods and Results: We profiled 754 miRNAs in baseline plasma samples of 36 hypertensive European American adults treated with hydrochlorothiazide, categorized into responders (n=18) and nonresponders (n=18) on the basis of diastolic blood pressure response to hydrochlorothiazide. miRNAs with ≥2.5‐fold differential expression between responders and nonresponders were considered for validation in 3 cohorts (n=50 each): hydrochlorothiazide‐treated European Americans, chlorthalidone‐treated European Americans, and hydrochlorothiazide‐treated Black individuals. Different blood pressure phenotypes including categorical (responder versus nonresponder) and continuous diastolic blood pressure and systolic blood pressure were tested for association with the candidate miRNA expression using multivariate regression analyses adjusting for age, sex, and baseline blood pressure. After quality control, 74 miRNAs were available for screening, 19 of which were considered for validation. In the validation cohort, miR‐193b‐3p and 30d‐5p showed significant associations with continuous SBP or diastolic blood pressure response or both, to hydrochlorothiazide in European Americans at Benjamini‐Hochberg adjusted P P <0.05. Predicted target genes of the 5 miRNAs were mapped to key hypertension pathways: lysine degradation, fatty acid biosynthesis, and metabolism. Conclusions: The above identified circulating miRNAs may have a potential for clinical use as biomarkers for thiazide diuretic selection in hypertension. Registration: URL: ClinicalTrials.gov . Unique identifiers: NCT00246519 , NCT01203852 , NCT00005520 .


  • Open Access

    Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients

    by Lakshmi Manasa S. Chekka, Rhonda M. Cooper‐DeHoff, John G. Gums, Arlene B. Chapman, Julie A. Johnson

    This study conducted a pairwise comparison of antihypertensive and metabolic effects of hydrochlorothiazide (HCTZ) and chlorthalidone (CTD) at 25 mg/day in the same individuals to address the clinical dilemma on preferred thiazide for hypertension (HTN) management. We included 15 African American (AA) and 35 European American (EA) patients with HTN treated with HCTZ and CTD as part of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR‐2 trials, respectively. Mean reduction in systolic/diastolic blood pressure (SBP/DBP) with HCTZ versus CTD was 8/5 versus 16/8 mmHg among EA patients (p < 1.0e−5 SBP, p = 0.002 DBP) and 11/8 versus 20/11 mmHg among AA patients (p = 0.03 SBP, p = 0.22 DBP). While CTD showed clinically meaningful benefit over HCTZ in two‐thirds of participants with respect to SBP reduction and half of EA patients with respect to DBP reduction, a majority of AA patients (53%) showed similar DBP reduction with both thiazides. Sixty percent of AA patients and 29% of EA patients attained blood pressure (BP) p = 0.0002) and AA patients (0.49, p = 0.043). While 31% of AA patients developed severe hypokalemia on CTD, <5% of others developed severe hypokalemia. Although 46% of AA patients on CTD required K+ supplementation, only 6%–11% of others required supplementation. Overall, in the majority of EA patients, CTD was superior to HCTZ, whereas among AA patients, it was superior in a minority, and was associated with significant potassium‐related risk, suggesting that guideline preferences for CTD over HCTZ are reasonable in EA patients but may be less reasonable in AA patients, particularly if the target is <140/90 mmHg.


  • Open Access

    Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients

    by Mai Mehanna, Caitrin W. McDonough, Steven M. Smith, Yan Gong, John G. Gums, Arlene B. Chapman, Julie A. Johnson, Rhonda M. Cooper-DeHoff

    Patients with higher genetic West African ancestry (GWAA) have hypertension (HTN) that is more difficult to treat and have higher rates of cardiovascular diseases (CVD) and differential responses to antihypertensive drugs than those with lower GWAA. The mechanisms underlying these disparities are poorly understood. Using data from 84 ancestry-informative markers in US participants from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR-2 trials, the GWAA proportion was estimated. Using multivariable linear regression, the baseline levels of 886 metabolites were compared between PEAR participants with GWAA < 45% and those with GWAA ≥ 45% to identify differential metabolites and metabolic clusters. Metabolites with a false discovery rate (FDR) < 0.2 were used to create metabolic clusters, and a cluster analysis was conducted. Differential clusters were then tested for replication in PEAR-2 participants. We identified 353 differential metabolites (FDR < 0.2) between PEAR participants with GWAA < 45% (n = 383) and those with GWAA ≥ 45% (n = 250), which were used to create 24 metabolic clusters. Of those, 13 were significantly different between groups (Bonferroni p < 0.002). Four clusters, plasmalogen and lysoplasmalogen, sphingolipid metabolism and ceramide, cofactors and vitamins, and the urea cycle, were replicated in PEAR-2 (Bonferroni p < 0.0038) and have been previously linked to HTN and CVD. Our findings may give insights into the mechanisms underlying HTN racial disparities.


  • Survey of direct patient care and payment models among pharmacy practice faculty

    by Thomas C. Dowling, Aaron Thomas, John G. Gums

    Introduction: The scope of pharmacy practice continues to expand into comprehensive medication management and direct patient care models, where practice‐based faculty play a central role. The extent to which schools/colleges of pharmacy have faculty embedded in health systems, physician practices, and other value‐based care settings involving practice plans is largely unknown.Objectives: The objectives of this project were to: (1) elucidate the perceptions, barriers, and implementation strategies related to direct patient care models, and (2) to further our understanding of how practice departments are employing practice plans, within schools/colleges of pharmacy.Methods: A 25‐item survey was distributed via email. Eligible respondents were pharmacy practice department chairs at United States‐based colleges/schools of pharmacy. Descriptive statistics were used to characterize workload allocations, direct patient care activities, and billing/reimbursement trends among practice faculty.Measurements and Main Results: Survey respondents included 43 institutions (32.6% institutional response rate) representing 1241 practice faculty and nearly 800 faculty involved in direct patient care activities. Faculty at private institutions tended to have a higher degree of effort in direct patient care (26.3% vs 4.3%) and were more involved in billing for services in the clinic setting, when compared with public institutions. Although Collaborative Practice Agreements were widely utilized, very few institutions employed practice revenue plans.Conclusion: The findings of our study indicate that pharmacy practice faculty provide significant effort in direct patient care that is critical to advancing the profession. These faculty practicing in primary and ambulatory care settings serve as role models to our student trainees, particularly in value‐based care settings. However, practice plan payment models appear to be rarely utilized. Failure to account for and recognize these valuable direct patient care activities may adversely impact the financial sustainability of schools and colleges of pharmacy in the future.


  • Open Access

    Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients

    by Mai Mehanna, Caitrin W. McDonough, Steven M. Smith, Yan Gong, John G. Gums, Arlene B. Chapman, Julie A. Johnson, Lauren McIntyre, Rhonda M. Cooper-DeHoff

    Plasma renin activity (PRA) is a predictive biomarker of blood pressure (BP) response to antihypertensives in European–American hypertensive patients. We aimed to identify the metabolic signatures of baseline PRA and the linkages with BP response to β-blockers and thiazides. Using data from the Pharmacogenomic Evaluation of Antihypertensive Responses-2 (PEAR-2) trial, multivariable linear regression adjusting for age, sex and baseline systolic-BP (SBP) was performed on European–American individuals treated with metoprolol (n = 198) and chlorthalidone (n = 181), to test associations between 856 metabolites and baseline PRA. Metabolites with a false discovery rate (FDR) < 0.05 or p < 0.01 were tested for replication in 463 European–American individuals treated with atenolol or hydrochlorothiazide. Replicated metabolites were then tested for validation based on the directionality of association with BP response. Sixty-three metabolites were associated with baseline PRA, of which nine, including six lipids, were replicated. Of those replicated, two metabolites associated with higher baseline PRA were validated: caprate was associated with greater metoprolol SBP response (β = −1.7 ± 0.6, p = 0.006) and sphingosine-1-phosphate was associated with reduced hydrochlorothiazide SBP response (β = 7.6 ± 2.8, p = 0.007). These metabolites are clustered with metabolites involved in sphingolipid, phospholipid, and purine metabolic pathways. The identified metabolic signatures provide insights into the mechanisms underlying BP response.


  • Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone

    by Lakshmi Manasa S. Chekka, Arlene B. Chapman, John G. Gums, Rhonda M. Cooper-DeHoff, Julie A. Johnson